ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Triple Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Contact: Study coordinator (Ashley Trumbull) · ashley.lynn.trumbull@emory.edu · 404-778-3969
Contact: Study coordinator (Kathleen Coleman) · kathleen.marie.coleman@emory.edu

Study leads

Kevin Kalinsky, M.D, M.S
Principal Investigator
Emory University Winship Cancer Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sacituzumab Govitecan In TNBC

Invasive Breast Cancer · Triple Negative Breast Cancer · ER-Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Boston, United States · Boston, United States

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

London, United Kingdom · London, United Kingdom

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Triple Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Metastatic Breast Cancer · Triple Negative Breast Cancer · Estrogen-receptor-low Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Atlanta, United States · Carmel, United States